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Abstract
A rapid and accurate method to detect and quantify Leishmania parasite is urgently needed to facilitate early diagnosis of
Leishmaniasis and monitoring of antileishmania therapy. In this study, real-time assay was applied to estimate parasite load
in clinical samples of visceral leishmaniasis (VL) and post kala-azar dermal leishmaniasis (PKDL) patients. The mean parasite
load in blood of VL patients (n=31) was 8,372 parasites/ml, while the mean parasite load in bone marrow aspirate (BMA)
was 194,962 parasites/million nucleated cells (n=12). Parasite load was undetectable after treatment with amphotericin B
(n=9) in VL, while a residual parasite burden was detected in 2 of 6 patients following treatment with sodium antimony
gluconate. Further, circulating levels of IFN-c, TNF-a, IL-10, IL-6, IL-4 and IL-2 were analysed in VL patients (n=29) by
Cytometric Bead Array to evaluate correlation with parasitic load. Interestingly, IL-10 levels correlated significantly with
parasite load (r=0.82, P,0.0001). The mean parasite load in dermal lesions of PKDL patients was 9,502 parasites/mg tissue
DNA at pre-treatment stage (n=25), with no detectable parasites after therapy (n=5). Parasite burden was distinctly higher
(P,0.0001) in nodular lesions (n=12) (19,586 parasites/mg tissue DNA) compared to papular/macular lesions (n=13, 193
parasites/mg tissue DNA). Further, chronic PKDL lesions showed significantly (P=0.0166) higher parasite load in comparison
with acute lesions. Results indicate that chronic, nodular cases constitute the major parasite reservoir for anthroponotic
transmission. Our results establish that the high parasite load in VL is strongly correlated with a high level of IL-10,
implicating IL-10 as a marker of disease severity. The assay is applicable for diagnosis as well as prognosis of both VL and
PKDL, providing a simple molecular tool to monitor the efficacy of antileishmanial drugs or vaccines.
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Introduction
The protozoan parasites of the genus Leishmania are the
causative agents of a group of diseases called leishmaniasis,
endemic in more than 88 countries and affecting 12 million people
worldwide. Depending on the species, Leishmania produce a wide
spectrum of diseases, from simple cutaneous, mucocutaneous to
deadly visceral leishmaniasis (VL). The visceral form of the disease,
caused by L. donovani, L. infantum, and L. chagasi, is prevalent in
tropical regions, with more than 90% of total cases reported from
Bangladesh, Brazil, India, and Sudan [1]. In India, the state of
Bihar, parts of Eastern Uttar Pradesh, and West Bengal are
endemic foci of VL where periodic epidemics are common
claiming the lives of thousands and causing severe morbidity to
hundreds of thousands [2]. This burden is further compounded in
India as about 5–15% of apparently cured VL patients develop an
unusual dermal form of the disease termed Post kala azar dermal
leishmaniasis (PKDL) [3]. The need to search for cases of PKDL
and treat them as a part of VL control program has been
emphasized since patients with PKDL provide the only known
reservoir for the parasite during inter-epidemic periods of VL in
India [4].
Current diagnostic methods based on parasite detection (stained
smears, culture or histopathology) are invasive and have poor
sensitivity, while immunological methods (Direct Agglutination
Test, enzyme-linked immunosorbent assay etc.) have limited
specificity, fail to distinguish between past and present infections
because of persistence of antibodies, and are not reliable in
immune-compromised patients [5]. In recent years, PCR has been
applied successfully to detect Leishmania spp. in cases with any of
the clinical manifestations of leishmaniasis. Several PCR protocols
for combined detection and differentiation of parasites exist,
including multiplex PCR [6], PCR plus sequencing [7], and
restriction fragment length polymorphism (RFLP) analysis [8].
However, the multiple steps of post-PCR manipulation in these
procedures require time and pose the risk of DNA contamination.
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parasite load in VL and PKDL lesion tissues would greatly
enhance the clinical management of the disease. Real-time PCR is
reported as a promising tool for detection and quantification of
various parasites including Toxoplasma gondii [9], Trypanosoma cruzi
[10] and Plasmodium spp. [11]. Previously, quantification of
Leishmania spp. in mouse tissues was determined using TaqMan
PCR method [12,13] or SYBR Green real-time assay [14]. There
are limited reports using real-time PCR for diagnosis and
quantification of Leishmania spps in humans [15–19], while such
studies are lacking in human VL and PKDL caused by L. donovani.
It is of interest to evaluate the association of parasitic burden
with immune response in human VL, since immune modulators
are considered to play a major role in the disease pathogenesis
[20]. In murine model, it is generally accepted that Th1 type
response is needed for control and protection against Leishmania
infections, and interferon gamma (IFN-c) secreted by Th1 cells, is
the most potent macrophage-activating cytokine leading to host
resistance to infection with Leishmania parasites [21]. Human
studies on immune response in VL have shown increased levels of
serum IFN-c, tumor necrosis factor alpha (TNF-a), interleukin
(IL)-1, IL-6, and IL-10 [22–26], however, the presence of high
levels of both IFN-c and IL-10 during active VL creates a puzzle
in understanding the disease pathogenesis [27,28].
In the present study, real time PCR assay was established for
diagnosis and measuring parasite load in VL and PKDL patients.
The study was extended to measure the parasite burden at post
treatment stage in order to monitor the efficacy of treatment. We
demonstrate a strong correlation of parasite burden with the host
immune response in VL and the pattern of parasite load with
respect to the clinical presentation in PKDL.
Materials and Methods
Patients and samples
Patients of VL and PKDL originated from Bihar and reported
to Departments of Medicine or Dermatology, Safdarjung
Hospital, New Delhi were included in this study. Confirmed VL
cases (either LD positive in BMA or PCR positive) and PKDL
patients (LD positive or PCR positive) were included in this study.
The profile of patients in the study is described in Table 1 and 2.
Blood samples (n=20) from healthy volunteers and dermal tissues
from leprosy patients (n=15) were collected as controls. Patients of
VL were given treatment with SAG (20 mg/kg/day) for 28 days or
Amp B (0.75–1.0 mg/kg/day) for 15—20 infusions on alternate
days. PKDL cases were treated with SAG (20 mg/kg/day) for 4
months. Clinical samples were taken before starting treatment and
one day after the last dose of treatment.
Ethics Statement
The study was approved by and carried out under the guidelines
of the Ethical Committee of the Safdarjung Hospital, India. All
patients or responsible adults provided written informed consent
for the collection of samples and subsequent analysis.
DNA isolation
Blood and bone marrow sample was collected in heparinized
tubes. DNA extraction was performed by using a QIAamp DNA
Blood mini kit (Qiagen, Germany) according to manufacturer’s
instructions. In order to achieve maximum yield, digestion was
performed overnight with proteinase K in Qiagen lysis solution
ALS. DNA was isolated from 200 mL of blood and eluted in 50 mL
distilled water. In case of BMA sample, 100 mL of BMA was used
and eluted in 100 mL distilled water. PKDL tissue was collected in
NET buffer [150 mM NaCl, 15 mM Tris-HCl (pH 8.30) and
1 mM EDTA]. Tissue was homogenized using liquid nitrogen
with pestle and mortar. DNA extraction from homogenized tissue
was performed by using QIAamp DNA Tissue kit according to
manufacturer’s instructions. DNA was eluted in 100 mL distilled
water. All samples were processed on the same day and DNA was
stored at 80uC until use.
Real-time PCR assay
Real-time PCR based on SYBR Green I was applied for
accurate quantification of the target sequence in the current study.
Genus specific primers based on kDNA were designed by using
Primer Express software 2.0 (Applied Biosystems, USA) and
consisted of 59-CTTTTCTGGTCCTCCGGGTAGG-39 (for-
ward), and 59-CCACCCGGCCCTATTTTACACCAA-39 (re-
verse). These primers were found to match with those used in the
quantification study of L. infantum DNA in blood samples of VL by
a real-time PCR assay based on TaqMan probe [16]. A standard
curve was constructed using 10-fold serially diluted L. donovani
parasite DNA corresponding to 10
4 to 0.1 parasite per reaction.
Amplification and detection were performed using an ABI Prism
7000 sequence detection system (Applied Biosystems, USA).
Standards, samples, and negative controls were analyzed in
triplicate for each run. A 10 ml of the PCR reaction was
performed, consisting of 16 SYBR Green I PCR Master mix
(Applied Biosystems, USA), 5 pmol forward primer, 5 pmol
reverse primer, and 1 ml volume of DNA from the blood, BMA
and tissue sample. Cycling parameters were 50uC for 2 min, 95uC
for 10 min, and 40 cycles at 95uC for 15 s and 60uC for 1 min. A
threshold cycle value (Ct) was calculated for each sample by
determining the point at which the fluorescence exceeded the
threshold limit. A standard curve was obtained by plotting the Ct
values against each standard of known concentration parasite
DNA. Each real time PCR reaction was carried out in triplicate.
Quantification of the human albumin gene in BMA
samples
In order to allow a comparison of parasite loads between the
different BMA samples, we quantified the number of nucleated
human cells using housekeeping gene (Albumin). We used primers,
forward- 59 GCT GTC ATC TCT TGT GGG CTG T 39
(100 pmol) and reverse- 59GGA GAG ATT TGT GTG GGC
ATG ACA 39 (100 pmol) and thermal profile was identical to
those of kinetoplast DNA amplification [16]. The standard curve
was established from DNA extracted from the THP-1 human
monocytic cell line.
Cytokine measurement
Whole blood, collected in sterile tubes at pre-treatment stage,
was allowed to coagulate for 2 to 3 h at 4uC prior to
centrifugation. Sera were preserved at 270uC until cytokine
measurement was performed using Cytometeric bead array (CBA)
kit (BD Biosciences, USA) as per manufacturer’s instructions.
Briefly, 50 ml of bead populations with discrete fluorescence
intensities of Peridinin chlorophyll protein (PerCP)-Cy5.5 and
coated with cytokine specific capture antibodies was added to
50 ml of patient sera, and 50 ml of phycoerythrin-conjugated anti-
human Th1/Th2 cytokine antibodies. Simultaneously, standards
for each cytokine (0–5000 pg/ml) were likewise mixed with
cytokine capture beads and phycoerythrin-conjugated reagent.
The vortexed mixtures were allowed to incubate for 3 hrs. Beads
were washed and analyzed using flowcytometry (FACS Calibur,
BD Biosciences, USA). Quantity (pg/ml) of respective cytokine
Parasite Load in Leishmaniasis
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from the cytokine standards supplied with the kit. The lower limit
of detection ranged from 1 to 2.1 pg/ml for different cytokines.
Statistical analysis
The differences between experimental groups were analyzed
using the Mann-Whitney test. Correlation was evaluated using
Spearman/Pearson correlation test. All data are presented as
mean 6 SD and a difference in mean values was considered
significant when the P value was ,0.05.
Results
Sensitivity and linearity of the Real-time PCR assay
Initially, the sensitivity of the assay was determined by serially
diluted known amount of parasite DNA (10 ng – 1fg). The
reaction allowed a detection limit of 1 fg DNA, corresponding to
0.01 parasite (data not shown), permitting the detection of 0.01
parasite per reaction. The mean standard curve was linear over 6
log range of DNA concentrations with correlation coefficient (r
2)o f
0.988 (Fig 1A). The intra-assay coefficient of variations of Ct
values among the replicates was 3.92, 1.44, 1.37, 0.67, 0.41 and
0.72 for six different concentrations. The mean standard curve
with DNA from THP-1 cells was also linear over 5 log range of
DNA concentrations with a correlation coefficient (r
2) of 0.987
(Fig 1B). A negative control (water instead of template DNA) with
each PCR assay was included for stringent measures to control
contamination.
Analysis of parasite load in Blood and BMA of VL patients
Evaluation of parasite load was carried out in clinical samples of
VL patients at pre-treatment (n=31) and post-treatment stage
(n=15). At the time of diagnosis, the mean parasite load in blood
was 8,372 parasites/ml with a wide range of 39 parasites/ml to
2.1610
5 parasites/ml (Table 1). There was no parasite detected in
blood samples from healthy persons (n=20). Evaluation of
Table 1. Results of real-time PCR assay for Leishmania DNA in blood samples of VL patients.
Patient no. Age/Sex Microscopy with BMA Region Ct±S.D. Parasite load/ml Blood
1 24/M N H 29.7060.24 39
2 42/M N L 29.4760.36 39
3 23/F N H 29.3160.3 43
4 6/M N L 29.1760.49 48
5 18/F ND L 28.8160.28 60
6 42/F P H 28.1760.36 92
7 16/M N H 27.6560.37 131
8 11/M N H 27.3160.67 164
9 7/M N L 27.2460.18 171
10 13/M P H 27.2360.31 172
11 25/F P L 27.2260.23 173
12 12/M P H 26.8360.15 225
13 48/M P L 26.5560.16 270
14 17/F N H 26.5061.09 281
15 63/M P H 26.3460.43 312
16 17/M N L 26.2361.0 336
17 12/M P L 26.0760.66 372
18 4/F N H 26.0560.14 377
19 15/M N L 25.9760.59 399
20 4/M P H 25.7960.77 450
21 11/M N L 23.5960.33 1939
22 8/F P H 23.0460.87 2801
23 6/F P L 22.8760.50 3130
24 7/M P H 22.8560.38 3165
25 12/M P H 22.6360.70 3663
26 35/M P H 22.6160.31 3729
27 7/M P L 22.4960.8 4021
28 40/F P H 21.9160.30 5939
29 19/M P L 21.8460.45 6195
30 9/F N H 21.2560.19 9171
31 14/F P H 16.5360.48 211613
M- Male, F-Female, P- Positive,N- Negative, ND- Not Determined, H- region of High.
endemicity, L- region of Low endemicity, Ct- Threshold cycle, S.D.- Standard deviation.
doi:10.1371/journal.pone.0010107.t001
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parasites/million nucleated cells with a range of 106 parasites to
10.9610
5 parasites/million nucleated cells (Table 2). Parasite
levels in blood and BMA showed a good correlation (r=0.76). The
microscopically positive cases had significantly higher (P=0.0152)
parasite load in blood (mean=14,490 parasites/ml) in comparison
with negative cases (mean=1,010 parasites/ml). Likewise micro-
scopically positive cases had significantly higher (P=0.0480)
parasite load in BMA (mean=372,589 parasites/million nucleated
cells) than microscopically negative cases (mean=68,085 para-
sites/million nucleated cells). There was no significant difference in
parasite load in either blood (P=0.6309) or BMA (P=0.4848)
between cases from low and high endemic regions.
Further, parasite load was also determined after treatment in
patients treated with SAG (n=6) or Amp B (n=9). At post-
treatment stage, parasites were detected in blood samples of 2
patients (no. 23 and 25), both treated with SAG, with parasite load
as 166 and 415 parasites/ml respectively. Microscopy with BMA
at post-treatment stage was negative for patient 23 but positive for
patient 25 who was further treated with Amp B.
Table 2. Results of real-time PCR assay for Leishmania DNA in BMA samples of VL patients.
S. no. Patient no. Microscopy with BMA Region Parasite load per million nucleated cells
12 N L 4 3 1
23 N H 7 1 5
34 N L 1 0 6
47 N H 3 3 2
5 10 P H 2849
6 13 P L 53818
7 14 N H 444518
8 15 P H 1091315
9 16 N L 23772
10 17 P L 31857
11 19 N L 6720
12 26 P H 683106
N-Negative, P-Positive, H- region of High endemicity, L- region of Low endemicity.
doi:10.1371/journal.pone.0010107.t002
Figure 1. Standard curves obtained with SYBR Green 1 based real time PCR. (A) Amplification of Leishmania DNA expressed as the number
of parasites per reaction. (B) Amplification of THP-1 cell line DNA expressed as the number of human nucleated cells per reaction.
doi:10.1371/journal.pone.0010107.g001
Parasite Load in Leishmaniasis
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Leishmania DNA was detected in lesion tissue of all the 25
patients of PKDL. The mean value of parasite load was 9,502
parasites/mg tissue DNA with range of 2 to 144,586 parasites/mg
tissue DNA (Table 3), while all leprosy lesions (n=15) were
negative. Comparative assessment of parasite load in various
clinical polymorphic forms of PKDL revealed significantly higher
(P,0.0001) parasite load in nodular lesions (n=12) with a mean of
19,586 parasites/mg tissue DNA as compared to parasite load in
papular/macular lesions (n=13), which had a mean of 193
parasites/mg tissue DNA. Further, correlation of parasite load was
also evaluated with the chronicity of PKDL lesions. There was
significantly (P=0.0166) lower parasite load in acute cases with
history of less than 3 years (n=12, mean=440 parasites/mg tissue
DNA) in comparison with chronic cases with history of more than
3 years (n=13, mean=17,867 parasites/mg tissue DNA). Overall,
real-time was positive in all the patients (100%), while slit smear
microscopy showed 50% positivity. Further, direct microscopy was
differentially analyzed in various polymorphic forms of PKDL
such as papular/macular and nodular lesions. Positivity for slit
smear in papular/macular and nodular was 38% and 63%
respectively. The parasite load was comparable in patients from
region of low and high endemicity (P=0.5187). There was no
parasite detected in tissue samples taken at post treatment stage
(n=5). Scatter plot of parasite load in VL (Blood, BMA) and
PKDL lesion tissues is shown in Fig 2.
Correlation of immune response with parasite load
Expression levels of IFN-c, TNF-a, IL-10, IL-6, IL-4 and IL-2
were analyzed in sera of VL patients (n=29) by CBA. The level of
IL-10 was significantly higher (P,0.0001) in cases with high
parasite load with correlation coefficient r=0.82 (Fig. 3A). No
correlation with parasite load was observed for other cytokines
examined. The levels of two major cytokines implicated in VL,
IFN-c and IL-6, with respect to parasite load are shown in Fig 3B.
Discussion
Reliable and rapid diagnostic and prognostic tools are
desperately needed for an effective control of VL. The sensitivity,
specificity and reproducibility of our PCR assay were comparable
or better as compared to other real time PCR studies [15–19].
Reproducibility of the results was high as assessed through
estimation of mean Ct values, SDs and intra-assay coefficient of
variations. In the current study, a wide range of parasite burden
was observed in peripheral blood as well as BMA of VL patients
irrespective of their origin from areas of high or low endemicity.
The real-time PCR assay was positive in all VL and PKDL cases
while direct microscopy was positive in 57% VL cases and 50%
Table 3. Clinical presentation and results of real-time PCR assay in dermal lesions of PKDL patients.
Patient no. Age/Sex Region
Clinical
presentation
Duration of
chronicity Slit Smear Ct±S.D.
Parasite Load/mg tissue
DNA
1 45/M H Papular 2 Months N 25.0260.12 39
2 10/M H Papular 6 Months N 22.4460.07 82
3 25/M H Papular 7 Months N 21.9660.38 50
4 12/M H Macular 1.5 Year P 22.6960.64 82
5 20/F H Papular 2 Years P 22.2560.23 105
6 16/M L Macular 3 Years N 25.6160.45 14
7 65/M H Papular 3 Years N 25.1560.96 2
8 18/M H Papular 3 Years P 23.8261.29 39
9 60/M H Papular 3 Years N 19.5560.76 603
10 21/M H Papular 4 Years N 25.7161.24 11
11 19/M L Papular 4 Years P 21.7960.29 461
12 18/M H Papular 6 Years P 21.6460.53 1022
13 22/M H Papular 10 Years N 28.7360.59 2
14 19/M L Nodular 1.5 Years P 19.5860.04 522
15 30/F H Nodular 2 Years N 16.4360.23 3022
16 14/M H Nodular 2.5 Years P 19.4860.98 719
17 17/M H Nodular 4 Years P 20.1360.07 966
18 27/M L Nodular 4 Years P 13.4360.20 144586
19 35/M H Nodular 6 Years P 19.1560.40 499
20 35/M H Nodular 6 Years P 16.3060.82 5180
21 28/M H Nodular 6 Years N 16.6260.52 3926
22 28/M L Nodular 7 Years N 16.5761.26 1512
23 52/M H Nodular 7 Years ND 16.1860.60 14870
24 19/M H Nodular 7 Years N 15.3660.37 12945
25 26/F H Nodular 10 Years P 11.6160.75 46286
M- Male, F-Female, P- Positive, N- Negative, ND- Not Determined, H- region of High endemicity, L- region of low endemicity.
doi:10.1371/journal.pone.0010107.t003
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were often negative in microscopic examination. Being more
economical as compare to TaqMan based real-time PCR, the
assay is applicable as a rapid, reliable diagnostic and prognostic
tool in reference labs for samples from remote or poorly equipped
endemic areas.
A wide range of parasite burden was observed in dermal tissues
of PKDL patients with nodular lesions showing significantly higher
parasite load in comparison with macular/papular lesions.
Previously, it has been reported that Leishmania parasites are
scanty and difficult to demonstrate in skin lesions with macular/
papular presentation [29]. The current study confirmed these
observations and presented quantification of parasite burden by
real-time PCR which is more accurate as compared to microscopic
assessment. Direct microscopy with slit smears of PKDL lesions is
reported to have low sensitivity (13–60%) [30]. We made similar
observations in slit smear of PKDL patients with 38% positivity in
patients with macular/papular and 63% in nodular lesions. Under
such circumstances, establishing the diagnosis of PKDL and
differentiating it from leprosy by traditional methods becomes
difficult particularly for macular/papular cases and real time PCR
assay provides a reliable alternative, being faster than routine
PCR. Further, parasitic load was substantially higher in chronic
lesions as compared to acute lesions suggesting that parasitic load
is increasing with time. This is in contrast to the situation in CL
where parasite load is higher in acute lesions in comparison to late
lesions [31]. The present data indicates that chronic/nodular skin
lesions rich in LD bodies, may be the main source of vector
infection in the community particularly in the absence of animal
reservoir, and play an important role in the disease transmission
from humans to the insect.
Clinical outcome of the disease is a consequence of the complex
interaction between the pathogen and the host and survival of
pathogen largely depends on the type of cytokine (Th1 or Th2)
being produced by host immune cells on encounter. We therefore
analyzed the major Th1/Th2 cytokines in VL patients to
understand the correlation of immune response with parasite
load. Our study revealed significantly elevated IL-10 levels,
strongly correlating with increasing parasitic load in VL patients.
An extreme case with unusually high IL-10 level also presented
with the highest parasite load. Similar observation was reported
earlier with L. donovani infection in murine models where it was
Figure 2. Scatter plot showing parasite load in Blood, BMA and
PKDL samples. Parasite load in VL blood samples (Parasites/ml blood)
and in BMA samples (Parasites/million nucleated cells) and in PKDL
lesion tissues (parasites/mg tissue DNA) were determined by real-time
PCR. Horizontal line represents the mean parasite load.
doi:10.1371/journal.pone.0010107.g002
Figure 3. Comparative assessment of IL-10, IFN-c, IL-6 and parasitic load in blood samples of VL patients. The serum levels (pg/ml) of
IL10 (Panel A) and IFN-c and IL-6 (Panel B) were measured by CBA and parasite load (Parasites/ml) determined by real-time PCR. Diagonal line
represents linear regression.
doi:10.1371/journal.pone.0010107.g003
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logarithmic parasite growth [32]. In canine VL, expression of IFN-
c, TNF-a, IL-10 and TGF-b in lymph nodes associated with
parasite load [20]. A recent study in canine VL has shown
association between expression level of IFN-c and IL-4 with
parasite load suggesting them as prognostic markers for monitor-
ing disease progression [33]. Further, the same group has shown a
correlation of parasite load with clinical manifestation of the
disease in canine VL [34]. We found a striking association of IL-10
with parasite load suggesting that IL-10 levels may be correlated
with disease severity in human VL. We have recently documented
a significant correlation between IL-4 expression and parasite load
in cutaneous leishmaniasis patients suggesting high IL-4 expression
may help in parasite survival by suppressing host immune
responses at the site of infection [31]. Functionally IL-10 is well
described as a suppressive or deactivating cytokine; in vitro, it has
been shown to inhibit antigen presentation [35], antigen-specific T
cell proliferation and type 1 cytokine production [36] and to
render macrophages refractory to activation by IFN-c for
intracellular killing [37]. The endogenous production of IL-10
has been shown to hinder the clearance of many other infectious
organisms including Klebsiella pneumoniae, Brucella abortus, Candida
albicans, Trypanosoma cruzi and Mycobacterium avium [38–42]. Role of
IL-10 in parasite persistence and establishing latency associated
with natural infection has been demonstrated using knockout mice
[43]. Previous studies including ours have documented elevated
levels of IL-10 in VL patients [23,28,44–46] and its association
with pathology [27,47]. Thus, IL-10 is well established as a critical
component in susceptibility to Leishmania infection that contributes
to the pathogenesis of VL by inhibiting the cytokine mediated
activation of immune responses. Our data demonstrates that IL-10
production, rather than any other cytokine, is a clear correlate of
severity of VL in human.
At post-treatment stage, parasites were undetectable in a
majority (87%) of VL patients; however, 2 out of 6 patients
treated with SAG had residual parasite in blood. One of these,
with parasite load as 415 parasites/ml after therapy, was found
positive with BMA microscopy and was further treated with Amp
B, while the other was lost to follow up. Our data are in agreement
with the reports that treatment failure is often associated with SAG
treatment, where most alarming reports came from Bihar, India
[48] that responded only to Amp B [49]. Therefore, the assay
could help in early detection of treatment failures and offers an
opportunity for point-of-care prognostic evaluation and monitor-
ing the efficacy of chemotherapy.
This study emphasizes that IL-10 production correlates with
parasitic burden in active human VL, making it a biomarker of
disease severity. Chronic/nodular cases of PKDL are demonstrat-
ed to have a high parasitic load, thus constituting the main
reservoir of the parasite in India. The real-time PCR assay has
immense application value as a rapid and accurate test for the
diagnosis and prognosis of both VL and PKDL. Further, the assay
provides an important molecular tool to monitor the efficacy of
anti-leishmanial therapy or vaccines.
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